# A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

> **NCT02358096** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 125 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes

## Interventions

- **DRUG:** ASP8232
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02358096
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-17
- **Primary completion:** 2016-10-26
- **Final completion:** 2017-03-15
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02358096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02358096, "A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02358096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*